世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

前立腺がん抗原3検査の世界市場インサイト、2030年までの予測


Global Prostate Cancer Antigen 3 Test Market Insights, Forecast to 2030

前立腺癌抗原3検査の世界市場規模は、2023年の5,169万米ドルから、2024〜2030年のCAGR 9.09%で、2030年には9,364万米ドルに達すると予測される。 米国とカナダの前立腺癌抗原3検査の市場規模は、2023年の1,910万... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2024年3月27日 US$4,900
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

前立腺癌抗原3検査の世界市場規模は、2023年の5,169万米ドルから、2024〜2030年のCAGR 9.09%で、2030年には9,364万米ドルに達すると予測される。
米国とカナダの前立腺癌抗原3検査の市場規模は、2023年の1,910万ドルから、2024年から2030年の予測期間中にCAGR 8.96%で、2030年には3,431万ドルに達すると推定される。
前立腺癌抗原3検査の中国市場は、2023年に750万ドルから増加し、2024年から2030年の予測期間中に11.03%のCAGRで、2030年までに1534万ドルに達すると推定される。
前立腺癌抗原3検査の欧州市場は、2024年から2030年の予測期間中に8.20%のCAGRで、2023年に1559万ドルから増加し、2030年までに2669万ドルに達すると推定される。
前立腺癌抗原3検査の世界的な主要企業は、Hologic社、サーモフィッシャーサイエンティフィック社、MDxHealth社、Exosome Diagnostics GmbH社、Creative Diagnostics社、Lytech社、YUBO社、MicroDiag Biomedicine社などである。2023年、世界の上位5社の売上高シェアは約82.81%であった。

レポートの内容
前立腺癌抗原3検査の世界市場規模を概観します。2019年~2023年の過去の市場収益データ、2024年の推定値、2030年までのCAGR予測による世界市場動向の分析。
前立腺癌抗原3検査の主要生産者を調査し、主要地域・国の収益も掲載しています。前立腺癌抗原3検査の今後の市場ポテンシャルと、この市場を様々なセグメントとサブセグメントに予測するための主要地域/国の注目点のハイライト。米国、カナダ、メキシコ、ブラジル、中国、日本、韓国、東南アジア、インド、ドイツ、英国、イタリア、中東、アフリカ、その他の国々の国別データと市場価値分析。

本レポートでは、2019年から2024年までのデータで、前立腺がん抗原3検査の収益、市場シェア、主要企業の業界ランキングに焦点を当てています。世界の前立腺癌抗原3検査市場における主要な利害関係者を特定し、その競争環境と市場ポジショニングを最近の動向とセグメント別の収益に基づいて分析します。本レポートは、利害関係者が競争状況を理解し、より多くの洞察を得て、より良い方法で事業と市場戦略を位置づけるのに役立ちます。

本レポートでは、2019年から2030年までのタイプ別、用途別のセグメントデータ、収益、成長率を分析しています。前立腺癌抗原3検査の収益、予測成長動向、生産技術、用途、エンドユーザー産業の市場規模を評価・予測します。
Hologic社、Thermo Fisher Scientific社、MDxHealth社、Exosome Diagnostics GmbH社、Creative Diagnostics社、Lytech社、YUBO社、MicroDiag Biomedicine社など、世界の主要企業の詳細な企業プロフィール。

市場セグメンテーション
企業別
ホロジック
サーモフィッシャーサイエンティフィック
MDxHealth
エクソソーム・ダイアグノスティックス
クリエイティブ・ダイアグノスティックス
ライテック
ユーボ
マイクロダイアグバイオメディシン

タイプ別セグメント
RT-PCR検査
ELISA検査

アプリケーション別
病院
診断センター
その他

地域別
北米
米国
カナダ

アジア太平洋
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア

ヨーロッパ
ドイツ
フランス
英国
イタリア
スペイン
その他のヨーロッパ

ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ

中東・アフリカ
中東
アフリカ

各章の概要
第1章: レポートのスコープ、各市場セグメント(製品タイプ、用途など)の市場規模、将来の発展可能性などのエグゼクティブサマリーを紹介。市場の現状と短期・中期・長期的な発展可能性についてハイレベルな見解を提供する。
第2章 前立腺癌抗原3検査の世界および地域レベルでの収益各地域と主要国の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、今後の発展見通し、市場スペース、生産能力などを紹介しています。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界各社が直面する課題とリスク、業界の関連政策の分析などを紹介します。
第3章:前立腺癌抗原3検査企業鈥の競争環境、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。
第4章:各種市場セグメントをタイプ別に分析し、各市場セグメントの収益、発展の可能性を網羅し、読者が各市場セグメントのブルーオーシャン市場を見つけるのに役立つ。
第5章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの収益、発展の可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。
第6章:北米(米国・カナダ):タイプ別、用途別、国別、セグメント別の収益。
第7章:ヨーロッパ:タイプ別、用途別、国別、セグメント別収益。
第8章:中国:タイプ別、用途別、セグメント別収益。
第9章:アジア(中国を除く):タイプ別、用途別、地域別、各セグメントの収益。
第10章:中東、アフリカ、ラテンアメリカ:タイプ別、用途別、国別、セグメント別収益。
第11章:主要企業のプロファイルを提供し、製品の説明や仕様、前立腺癌抗原3検査の収益、売上総利益率、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介する。
第12章:アナリストの視点/結論


ページTOPに戻る


目次

1 Report Overview 1
1.1 Study Scope 1
1.2 Market Analysis by Type 1
1.2.1 Global Prostate Cancer Antigen 3 Test Market Size Growth Rate by Type: 2019 VS 2023 VS 2030 1
1.2.2 RT-PCR 2
1.2.3 ELISA Test 3
1.3 Market by Application 3
1.3.1 Global Prostate Cancer Antigen 3 Test Market Share by Application: 2019 VS 2023 VS 2030 4
1.3.2 Hospital 5
1.3.3 Diagnosis Center 5
1.3.4 Others 5
1.4 Assumptions and Limitations 5
1.5 Study Objectives 6
1.6 Years Considered 7
2 Global Growth Trends 8
2.1 Global Prostate Cancer Antigen 3 Test Market Perspective (2019-2030) 8
2.2 Global Prostate Cancer Antigen 3 Test Growth Trends by Region 9
2.2.1 Global Prostate Cancer Antigen 3 Test Market Size by Region: 2019 VS 2023 VS 2030 10
2.2.2 Prostate Cancer Antigen 3 Test Historic Market Size by Region (2019-2024) 11
2.2.3 Prostate Cancer Antigen 3 Test Forecasted Market Size by Region (2025-2030) 12
2.3 Prostate Cancer Antigen 3 Test Market Dynamics 13
2.3.1 Prostate Cancer Antigen 3 Test Industry Trends 13
2.3.2 Prostate Cancer Antigen 3 Test Market Drivers 13
2.3.3 Prostate Cancer Antigen 3 Test Market Challenges 14
2.3.4 Prostate Cancer Antigen 3 Test Market Restraints 14
3 Competition Landscape by Key Players 15
3.1 Global Revenue Prostate Cancer Antigen 3 Test by Players 15
3.1.1 Global Prostate Cancer Antigen 3 Test Revenue by Players (2019-2024) 15
3.1.2 Global Prostate Cancer Antigen 3 Test Revenue Market Share by Players (2019-2024) 16
3.2 Global Prostate Cancer Antigen 3 Test Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 17
3.3 Global Key Players of Prostate Cancer Antigen 3 Test, Ranking by Revenue, 2022 VS 2023 VS 2024 18
3.4 Global Prostate Cancer Antigen 3 Test Market Concentration Ratio 19
3.4.1 Global Prostate Cancer Antigen 3 Test Market Concentration Ratio (CR5 and HHI) 19
3.4.2 Global Top 3 and Top 5 Companies by Prostate Cancer Antigen 3 Test Revenue in 2023 20
3.5 Global Key Players of Prostate Cancer Antigen 3 Test Head office and Area Served 21
3.6 Global Key Players of Prostate Cancer Antigen 3 Test, Product 21
4 Prostate Cancer Antigen 3 Test Breakdown Data by Type 22
4.1 Global Prostate Cancer Antigen 3 Test Historic Market Size by Type (2019-2024) 22
4.2 Global Prostate Cancer Antigen 3 Test Forecasted Market Size by Type (2025-2030) 23
5 Prostate Cancer Antigen 3 Test Breakdown Data by Application 24
5.1 Global Prostate Cancer Antigen 3 Test Historic Market Size by Application (2019-2024) 24
5.2 Global Prostate Cancer Antigen 3 Test Forecasted Market Size by Application (2025-2030) 25
6 North America 26
6.1 North America Prostate Cancer Antigen 3 Test Market Size (2019-2030) 26
6.2 North America Prostate Cancer Antigen 3 Test Market Size by Type 26
6.2.1 North America Prostate Cancer Antigen 3 Test Market Size by Type (2019-2024) 26
6.2.2 North America Prostate Cancer Antigen 3 Test Market Size by Type (2025-2030) 27
6.2.3 North America Prostate Cancer Antigen 3 Test Market Share by Type (2019-2030) 27
6.3 North America Prostate Cancer Antigen 3 Test Market Size by Application 28
6.3.1 North America Prostate Cancer Antigen 3 Test Market Size by Application (2019-2024) 28
6.3.2 North America Prostate Cancer Antigen 3 Test Market Size by Application (2025-2030) 28
6.3.3 North America Prostate Cancer Antigen 3 Test Market Share by Application (2019-2030) 29
6.4 North America Prostate Cancer Antigen 3 Test Market Size by Country 29
6.4.1 North America Prostate Cancer Antigen 3 Test Market Size by Country: 2019 VS 2023 VS 2030 29
6.4.2 North America Prostate Cancer Antigen 3 Test Market Size by Country (2019-2024) 30
6.4.3 North America Prostate Cancer Antigen 3 Test Market Share by Country (2025-2030) 30
6.4.4 United States 31
6.4.5 Canada 32
7 Europe 33
7.1 Europe Prostate Cancer Antigen 3 Test Market Size (2019-2030) 33
7.2 Europe Prostate Cancer Antigen 3 Test Market Size by Type 33
7.2.1 Europe Prostate Cancer Antigen 3 Test Market Size by Type (2019-2024) 33
7.2.2 Europe Prostate Cancer Antigen 3 Test Market Size by Type (2025-2030) 34
7.2.3 Europe Prostate Cancer Antigen 3 Test Market Share by Type (2019-2030) 34
7.3 Europe Prostate Cancer Antigen 3 Test Market Size by Application 35
7.3.1 Europe Prostate Cancer Antigen 3 Test Market Size by Application (2019-2024) 35
7.3.2 Europe Prostate Cancer Antigen 3 Test Market Size by Application (2025-2030) 35
7.3.3 Europe Prostate Cancer Antigen 3 Test Market Share by Application (2019-2030) 36
7.4 Europe Prostate Cancer Antigen 3 Test Market Size by Country 36
7.4.1 Europe Prostate Cancer Antigen 3 Test Market Size by Country: 2019 VS 2023 VS 2030 36
7.4.2 Europe Prostate Cancer Antigen 3 Test Market Size by Country (2019-2024) 37
7.4.3 Europe Prostate Cancer Antigen 3 Test Market Size by Country (2025-2030) 37
7.4.4 Germany 39
7.4.5 France 39
7.4.6 U.K. 40
7.4.7 Italy 40
7.4.8 Spain 41
8 China 42
8.1 China Prostate Cancer Antigen 3 Test Market Size (2019-2030) 42
8.2 China Prostate Cancer Antigen 3 Test Market Size by Type 42
8.2.1 China Prostate Cancer Antigen 3 Test Market Size by Type (2019-2024) 42
8.2.2 China Prostate Cancer Antigen 3 Test Market Size by Type (2025-2030) 43
8.2.3 China Prostate Cancer Antigen 3 Test Market Share by Type (2019-2030) 43
8.3 China Prostate Cancer Antigen 3 Test Market Size by Application 44
8.3.1 China Prostate Cancer Antigen 3 Test Market Size by Application (2019-2024) 44
8.3.2 China Prostate Cancer Antigen 3 Test Market Size by Application (2025-2030) 44
8.3.3 China Prostate Cancer Antigen 3 Test Market Share by Application (2019-2030) 45
9 Asia (excluding China) 46
9.1 Asia Prostate Cancer Antigen 3 Test Market Size (2019-2030) 46
9.2 Asia Prostate Cancer Antigen 3 Test Market Size by Type 46
9.2.1 Asia Prostate Cancer Antigen 3 Test Market Size by Type (2019-2024) 46
9.2.2 Asia Prostate Cancer Antigen 3 Test Market Size by Type (2025-2030) 47
9.2.3 Asia Prostate Cancer Antigen 3 Test Market Share by Type (2019-2030) 47
9.3 Asia Prostate Cancer Antigen 3 Test Market Size by Application 48
9.3.1 Asia Prostate Cancer Antigen 3 Test Market Size by Application (2019-2024) 48
9.3.2 Asia Prostate Cancer Antigen 3 Test Market Size by Application (2025-2030) 48
9.3.3 Asia Prostate Cancer Antigen 3 Test Market Share by Application (2019-2030) 49
9.4 Asia Prostate Cancer Antigen 3 Test Market Size by Region 49
9.4.1 Asia Prostate Cancer Antigen 3 Test Market Size by Region: 2019 VS 2023 VS 2030 49
9.4.2 Asia Prostate Cancer Antigen 3 Test Market Size by Region (2019-2024) 50
9.4.3 Asia Prostate Cancer Antigen 3 Test Market Size by Region (2025-2030) 50
9.4.4 Japan 51
9.4.5 South Korea 52
9.4.6 Southeast Asia 52
9.4.7 India 53
10 Middle East, Africa, and Latin America 54
10.1 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size (2019-2030) 54
10.2 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Type 54
10.2.1 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Type (2019-2024) 54
10.2.2 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Type (2025-2030) 55
10.2.3 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Share by Type (2019-2030) 55
10.3 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Application 56
10.3.1 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Application (2019-2024) 56
10.3.2 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Application (2025-2030) 56
10.3.3 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Share by Application (2019-2030) 57
10.4 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Country 57
10.4.1 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Country: 2019 VS 2023 VS 2030 57
10.4.2 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Country (2019-2024) 58
10.4.3 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Country (2025-2030) 58
10.4.4 Brazil 59
10.4.5 Mexico 60
10.4.6 Middle East 60
10.4.7 Africa 61
11 Key Players Profiles 62
11.1 Hologic 62
11.1.1 Hologic Company Details 62
11.1.2 Hologic Business Overview 62
11.1.3 Hologic Prostate Cancer Antigen 3 Test Introduction 63
11.1.4 Hologic Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 63
11.2 Thermo Fisher Scientific 64
11.2.1 Thermo Fisher Scientific Company Details 64
11.2.2 Thermo Fisher Scientific Business Overview 64
11.2.3 Thermo Fisher Scientific Prostate Cancer Antigen 3 Test Introduction 65
11.2.4 Thermo Fisher Scientific Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 65
11.3 MDxHealth 66
11.3.1 MDxHealth Company Details 66
11.3.2 MDxHealth Business Overview 66
11.3.3 MDxHealth Prostate Cancer Antigen 3 Test Introduction 67
11.3.4 MDxHealth Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 67
11.4 Exosome Diagnostics GmbH 67
11.4.1 Exosome Diagnostics GmbH Company Details 67
11.4.2 Exosome Diagnostics GmbH Business Overview 68
11.4.3 Exosome Diagnostics GmbH Prostate Cancer Antigen 3 Test Introduction 68
11.4.4 Exosome Diagnostics GmbH Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 69
11.5 Creative Diagnostics 69
11.5.1 Creative Diagnostics Company Details 69
11.5.2 Creative Diagnostics Business Overview 70
11.5.3 Creative Diagnostics Prostate Cancer Antigen 3 Test Introduction 70
11.5.4 Creative Diagnostics Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 71
11.6 Lytech 71
11.6.1 Lytech Company Details 71
11.6.2 Lytech Business Overview 72
11.6.3 Lytech Prostate Cancer Antigen 3 Test Introduction 72
11.6.4 Lytech Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 73
11.7 YUBO 73
11.7.1 YUBO Company Details 73
11.7.2 YUBO Business Overview 74
11.7.3 YUBO Prostate Cancer Antigen 3 Test Introduction 74
11.7.4 YUBO Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 75
11.8 MicroDiag Biomedicine 76
11.8.1 MicroDiag Biomedicine Company Details 76
11.8.2 MicroDiag Biomedicine Business Overview 76
11.8.3 MicroDiag Biomedicine Prostate Cancer Antigen 3 Test Introduction 77
11.8.4 MicroDiag Biomedicine Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 77
12 Analyst's Viewpoints/Conclusions 78
13 Appendix 79
13.1 Research Methodology 79
13.1.1 Methodology/Research Approach 79
13.1.2 Data Source 82
13.2 Author Details 85
13.3 Disclaimer 86

 

ページTOPに戻る


 

Summary

The global Prostate Cancer Antigen 3 Test market size is projected to reach US 93.64 million by 2030, from US$ 51.69 million in 2023, at a CAGR of 9.09% during 2024-2030.
The US & Canada market for Prostate Cancer Antigen 3 Test is estimated to increase from $ 19.1 million in 2023 to reach $ 34.31 million by 2030, at a CAGR of 8.96% during the forecast period of 2024 through 2030.
The China market for Prostate Cancer Antigen 3 Test is estimated to increase from $ 7.50 million in 2023 to reach $ 15.34 million by 2030, at a CAGR of 11.03% during the forecast period of 2024 through 2030.
The Europe market for Prostate Cancer Antigen 3 Test is estimated to increase from $ 15.59 million in 2023 to reach $ 26.69 million by 2030, at a CAGR of 8.20% during the forecast period of 2024 through 2030.
The global key companies of Prostate Cancer Antigen 3 Test include Hologic, Thermo Fisher Scientific, MDxHealth, Exosome Diagnostics GmbH, Creative Diagnostics, Lytech, YUBO, MicroDiag Biomedicine, etc. In 2023, the global top five players had a share approximately 82.81% in terms of revenue

Report Includes
This report presents an overview of global market for Prostate Cancer Antigen 3 Test market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Prostate Cancer Antigen 3 Test, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Prostate Cancer Antigen 3 Test, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Prostate Cancer Antigen 3 Test revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Prostate Cancer Antigen 3 Test market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Prostate Cancer Antigen 3 Test revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Hologic, Thermo Fisher Scientific, MDxHealth, Exosome Diagnostics GmbH, Creative Diagnostics, Lytech, YUBO, MicroDiag Biomedicine, and etc.

Market Segmentation
By Company
Hologic
Thermo Fisher Scientific
MDxHealth
Exosome Diagnostics GmbH
Creative Diagnostics
Lytech
YUBO
MicroDiag Biomedicine

Segment by Type
RT-PCR
ELISA Test

Segment by Application
Hospital
Diagnosis Center
Others

By Region
North America
United States
Canada

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia

Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe

Latin America
Mexico
Brazil
Rest of Latin America

Middle East & Africa
Middle East
Africa

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Prostate Cancer Antigen 3 Test in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Prostate Cancer Antigen 3 Test companies鈥 competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Prostate Cancer Antigen 3 Test revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions



ページTOPに戻る


Table of Contents

1 Report Overview 1
1.1 Study Scope 1
1.2 Market Analysis by Type 1
1.2.1 Global Prostate Cancer Antigen 3 Test Market Size Growth Rate by Type: 2019 VS 2023 VS 2030 1
1.2.2 RT-PCR 2
1.2.3 ELISA Test 3
1.3 Market by Application 3
1.3.1 Global Prostate Cancer Antigen 3 Test Market Share by Application: 2019 VS 2023 VS 2030 4
1.3.2 Hospital 5
1.3.3 Diagnosis Center 5
1.3.4 Others 5
1.4 Assumptions and Limitations 5
1.5 Study Objectives 6
1.6 Years Considered 7
2 Global Growth Trends 8
2.1 Global Prostate Cancer Antigen 3 Test Market Perspective (2019-2030) 8
2.2 Global Prostate Cancer Antigen 3 Test Growth Trends by Region 9
2.2.1 Global Prostate Cancer Antigen 3 Test Market Size by Region: 2019 VS 2023 VS 2030 10
2.2.2 Prostate Cancer Antigen 3 Test Historic Market Size by Region (2019-2024) 11
2.2.3 Prostate Cancer Antigen 3 Test Forecasted Market Size by Region (2025-2030) 12
2.3 Prostate Cancer Antigen 3 Test Market Dynamics 13
2.3.1 Prostate Cancer Antigen 3 Test Industry Trends 13
2.3.2 Prostate Cancer Antigen 3 Test Market Drivers 13
2.3.3 Prostate Cancer Antigen 3 Test Market Challenges 14
2.3.4 Prostate Cancer Antigen 3 Test Market Restraints 14
3 Competition Landscape by Key Players 15
3.1 Global Revenue Prostate Cancer Antigen 3 Test by Players 15
3.1.1 Global Prostate Cancer Antigen 3 Test Revenue by Players (2019-2024) 15
3.1.2 Global Prostate Cancer Antigen 3 Test Revenue Market Share by Players (2019-2024) 16
3.2 Global Prostate Cancer Antigen 3 Test Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 17
3.3 Global Key Players of Prostate Cancer Antigen 3 Test, Ranking by Revenue, 2022 VS 2023 VS 2024 18
3.4 Global Prostate Cancer Antigen 3 Test Market Concentration Ratio 19
3.4.1 Global Prostate Cancer Antigen 3 Test Market Concentration Ratio (CR5 and HHI) 19
3.4.2 Global Top 3 and Top 5 Companies by Prostate Cancer Antigen 3 Test Revenue in 2023 20
3.5 Global Key Players of Prostate Cancer Antigen 3 Test Head office and Area Served 21
3.6 Global Key Players of Prostate Cancer Antigen 3 Test, Product 21
4 Prostate Cancer Antigen 3 Test Breakdown Data by Type 22
4.1 Global Prostate Cancer Antigen 3 Test Historic Market Size by Type (2019-2024) 22
4.2 Global Prostate Cancer Antigen 3 Test Forecasted Market Size by Type (2025-2030) 23
5 Prostate Cancer Antigen 3 Test Breakdown Data by Application 24
5.1 Global Prostate Cancer Antigen 3 Test Historic Market Size by Application (2019-2024) 24
5.2 Global Prostate Cancer Antigen 3 Test Forecasted Market Size by Application (2025-2030) 25
6 North America 26
6.1 North America Prostate Cancer Antigen 3 Test Market Size (2019-2030) 26
6.2 North America Prostate Cancer Antigen 3 Test Market Size by Type 26
6.2.1 North America Prostate Cancer Antigen 3 Test Market Size by Type (2019-2024) 26
6.2.2 North America Prostate Cancer Antigen 3 Test Market Size by Type (2025-2030) 27
6.2.3 North America Prostate Cancer Antigen 3 Test Market Share by Type (2019-2030) 27
6.3 North America Prostate Cancer Antigen 3 Test Market Size by Application 28
6.3.1 North America Prostate Cancer Antigen 3 Test Market Size by Application (2019-2024) 28
6.3.2 North America Prostate Cancer Antigen 3 Test Market Size by Application (2025-2030) 28
6.3.3 North America Prostate Cancer Antigen 3 Test Market Share by Application (2019-2030) 29
6.4 North America Prostate Cancer Antigen 3 Test Market Size by Country 29
6.4.1 North America Prostate Cancer Antigen 3 Test Market Size by Country: 2019 VS 2023 VS 2030 29
6.4.2 North America Prostate Cancer Antigen 3 Test Market Size by Country (2019-2024) 30
6.4.3 North America Prostate Cancer Antigen 3 Test Market Share by Country (2025-2030) 30
6.4.4 United States 31
6.4.5 Canada 32
7 Europe 33
7.1 Europe Prostate Cancer Antigen 3 Test Market Size (2019-2030) 33
7.2 Europe Prostate Cancer Antigen 3 Test Market Size by Type 33
7.2.1 Europe Prostate Cancer Antigen 3 Test Market Size by Type (2019-2024) 33
7.2.2 Europe Prostate Cancer Antigen 3 Test Market Size by Type (2025-2030) 34
7.2.3 Europe Prostate Cancer Antigen 3 Test Market Share by Type (2019-2030) 34
7.3 Europe Prostate Cancer Antigen 3 Test Market Size by Application 35
7.3.1 Europe Prostate Cancer Antigen 3 Test Market Size by Application (2019-2024) 35
7.3.2 Europe Prostate Cancer Antigen 3 Test Market Size by Application (2025-2030) 35
7.3.3 Europe Prostate Cancer Antigen 3 Test Market Share by Application (2019-2030) 36
7.4 Europe Prostate Cancer Antigen 3 Test Market Size by Country 36
7.4.1 Europe Prostate Cancer Antigen 3 Test Market Size by Country: 2019 VS 2023 VS 2030 36
7.4.2 Europe Prostate Cancer Antigen 3 Test Market Size by Country (2019-2024) 37
7.4.3 Europe Prostate Cancer Antigen 3 Test Market Size by Country (2025-2030) 37
7.4.4 Germany 39
7.4.5 France 39
7.4.6 U.K. 40
7.4.7 Italy 40
7.4.8 Spain 41
8 China 42
8.1 China Prostate Cancer Antigen 3 Test Market Size (2019-2030) 42
8.2 China Prostate Cancer Antigen 3 Test Market Size by Type 42
8.2.1 China Prostate Cancer Antigen 3 Test Market Size by Type (2019-2024) 42
8.2.2 China Prostate Cancer Antigen 3 Test Market Size by Type (2025-2030) 43
8.2.3 China Prostate Cancer Antigen 3 Test Market Share by Type (2019-2030) 43
8.3 China Prostate Cancer Antigen 3 Test Market Size by Application 44
8.3.1 China Prostate Cancer Antigen 3 Test Market Size by Application (2019-2024) 44
8.3.2 China Prostate Cancer Antigen 3 Test Market Size by Application (2025-2030) 44
8.3.3 China Prostate Cancer Antigen 3 Test Market Share by Application (2019-2030) 45
9 Asia (excluding China) 46
9.1 Asia Prostate Cancer Antigen 3 Test Market Size (2019-2030) 46
9.2 Asia Prostate Cancer Antigen 3 Test Market Size by Type 46
9.2.1 Asia Prostate Cancer Antigen 3 Test Market Size by Type (2019-2024) 46
9.2.2 Asia Prostate Cancer Antigen 3 Test Market Size by Type (2025-2030) 47
9.2.3 Asia Prostate Cancer Antigen 3 Test Market Share by Type (2019-2030) 47
9.3 Asia Prostate Cancer Antigen 3 Test Market Size by Application 48
9.3.1 Asia Prostate Cancer Antigen 3 Test Market Size by Application (2019-2024) 48
9.3.2 Asia Prostate Cancer Antigen 3 Test Market Size by Application (2025-2030) 48
9.3.3 Asia Prostate Cancer Antigen 3 Test Market Share by Application (2019-2030) 49
9.4 Asia Prostate Cancer Antigen 3 Test Market Size by Region 49
9.4.1 Asia Prostate Cancer Antigen 3 Test Market Size by Region: 2019 VS 2023 VS 2030 49
9.4.2 Asia Prostate Cancer Antigen 3 Test Market Size by Region (2019-2024) 50
9.4.3 Asia Prostate Cancer Antigen 3 Test Market Size by Region (2025-2030) 50
9.4.4 Japan 51
9.4.5 South Korea 52
9.4.6 Southeast Asia 52
9.4.7 India 53
10 Middle East, Africa, and Latin America 54
10.1 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size (2019-2030) 54
10.2 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Type 54
10.2.1 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Type (2019-2024) 54
10.2.2 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Type (2025-2030) 55
10.2.3 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Share by Type (2019-2030) 55
10.3 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Application 56
10.3.1 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Application (2019-2024) 56
10.3.2 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Application (2025-2030) 56
10.3.3 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Share by Application (2019-2030) 57
10.4 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Country 57
10.4.1 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Country: 2019 VS 2023 VS 2030 57
10.4.2 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Country (2019-2024) 58
10.4.3 Middle East, Africa, and Latin America Prostate Cancer Antigen 3 Test Market Size by Country (2025-2030) 58
10.4.4 Brazil 59
10.4.5 Mexico 60
10.4.6 Middle East 60
10.4.7 Africa 61
11 Key Players Profiles 62
11.1 Hologic 62
11.1.1 Hologic Company Details 62
11.1.2 Hologic Business Overview 62
11.1.3 Hologic Prostate Cancer Antigen 3 Test Introduction 63
11.1.4 Hologic Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 63
11.2 Thermo Fisher Scientific 64
11.2.1 Thermo Fisher Scientific Company Details 64
11.2.2 Thermo Fisher Scientific Business Overview 64
11.2.3 Thermo Fisher Scientific Prostate Cancer Antigen 3 Test Introduction 65
11.2.4 Thermo Fisher Scientific Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 65
11.3 MDxHealth 66
11.3.1 MDxHealth Company Details 66
11.3.2 MDxHealth Business Overview 66
11.3.3 MDxHealth Prostate Cancer Antigen 3 Test Introduction 67
11.3.4 MDxHealth Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 67
11.4 Exosome Diagnostics GmbH 67
11.4.1 Exosome Diagnostics GmbH Company Details 67
11.4.2 Exosome Diagnostics GmbH Business Overview 68
11.4.3 Exosome Diagnostics GmbH Prostate Cancer Antigen 3 Test Introduction 68
11.4.4 Exosome Diagnostics GmbH Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 69
11.5 Creative Diagnostics 69
11.5.1 Creative Diagnostics Company Details 69
11.5.2 Creative Diagnostics Business Overview 70
11.5.3 Creative Diagnostics Prostate Cancer Antigen 3 Test Introduction 70
11.5.4 Creative Diagnostics Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 71
11.6 Lytech 71
11.6.1 Lytech Company Details 71
11.6.2 Lytech Business Overview 72
11.6.3 Lytech Prostate Cancer Antigen 3 Test Introduction 72
11.6.4 Lytech Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 73
11.7 YUBO 73
11.7.1 YUBO Company Details 73
11.7.2 YUBO Business Overview 74
11.7.3 YUBO Prostate Cancer Antigen 3 Test Introduction 74
11.7.4 YUBO Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 75
11.8 MicroDiag Biomedicine 76
11.8.1 MicroDiag Biomedicine Company Details 76
11.8.2 MicroDiag Biomedicine Business Overview 76
11.8.3 MicroDiag Biomedicine Prostate Cancer Antigen 3 Test Introduction 77
11.8.4 MicroDiag Biomedicine Revenue in Prostate Cancer Antigen 3 Test Business (2019-2024) 77
12 Analyst's Viewpoints/Conclusions 78
13 Appendix 79
13.1 Research Methodology 79
13.1.1 Methodology/Research Approach 79
13.1.2 Data Source 82
13.2 Author Details 85
13.3 Disclaimer 86

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療機器)の最新刊レポート

本レポートと同じKEY WORD(prostate cancer)の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/23 10:26

157.72 円

164.94 円

201.11 円

ページTOPに戻る